This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Long-term Safety Study of Once-daily Travatan

This study has been completed.
Information provided by (Responsible Party):
Alcon Research Identifier:
First received: January 3, 2003
Last updated: October 2, 2011
Last verified: April 2010
Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.

Condition Intervention Phase
Glaucoma, Open-angle Ocular Hypertension Drug: Travatan Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Long-term Safety Study of Once-daily TRAVATAN

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean Intraocular Pressure [ Time Frame: At 5 years. ]

    Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken.

    All IOP measurements were performed with a Goldmann applanation tonometer.

Enrollment: 502
Study Start Date: January 2006
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Travatan
Travoprost (0.004%)
Drug: Travatan
Travoprost (0.004%) 1 drop each eye once daily


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Adult patients of any race and either sex with chronic angle-closure glaucoma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00051168

United States, Texas
Fort Worth, Texas, United States
Sponsors and Collaborators
Alcon Research
  More Information

Responsible Party: Alcon Research Identifier: NCT00051168     History of Changes
Other Study ID Numbers: C-02-20
Study First Received: January 3, 2003
Results First Received: March 22, 2010
Last Updated: October 2, 2011

Keywords provided by Alcon Research:

Additional relevant MeSH terms:
Ocular Hypertension
Glaucoma, Open-Angle
Eye Diseases
Antihypertensive Agents processed this record on September 21, 2017